Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Inverness Medical Innovations Inc., a developer and marketer of health-management and monitoring technologies, has closed its $240 million acquisition of Concateno plc, a London-based provider of drug-testing services.
Waltham-based Inverness said it issued $150 million in senior notes to help fund the acquisition.
In its most recent financial quarter, Inverness (NYSE: IMA) booked $456.7 million in revenue, compared with $396.3 million in the year-earlier period. Around $14 million of that increase was linked to flu-test sales stemming from the H1N1 outbreak, the company said. Inverness’ cash and cash equivalents were $566.9 million as of June 30, compared with $144 million a year earlier. Much of that cash came in the form of long-term borrowings, which increased to $1.88 billion from $1.5 billion as of June 30, 2008.
Inverness first expressed interest in buying Concateno in June. Concateno’s “unique position” in the European point of care and drug-abuse testing market is a “perfect complement” to Inverness’ existing drug abuse business, which mostly operates in the U.S., the company claimed in a statement.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
